CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY ...Middle East

NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to...

Read More Details
Finally We wish PressBee provided you with enough information of ( CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY )

Also on site :

• Billboard’s 2025 Top Music Lawyers Revealed
• Semi-truck explosion, fire closes Interstate 65 in NW Indiana
• Cannes Film Festival’s Official Poster(s) For 2025 Honor Claude Lelouch’s ‘A Man And A Woman’